|
This is the second article in our series about travel medicine. It
examines the epidemiology, aetiology and symptoms of travellers' diarrhoea
and then describes the treatments available |
A drop hole toilet in Mozambique |
Summary of main points
|
Montezuma's Revenge, Aden Gut, Basra Belly . . . there is an almost endless list of names used to describe the syndrome referred to as travellers' diarrhoea (TD). Of all the travel health hazards, a bout of diarrhoea is the most likely. It has been estimated that 30 to 50 per cent of travellers from industrialised nations who visit developing countries will suffer from an episode of TD, representing around seven million individuals a year.1 Although it is usually a self limiting problem resolving within three to five days, there are some important considerations:
The high incidence of TD in developing countries is believed to be linked to problems concerning sanitation and food handling which, due to economic and other constraints, are not as well regulated as in industrialised nations. This has resulted in the concept that travellers should be educated in hygiene measures, about both food and water, in an attempt to reduce the incidence of TD. This will be dealt with in greater depth in the next article.
For the pharmacist, the most important issues are an understanding of both the potential role of prophylactic measures and the management of TD using oral rehydration, antimotility agents and antimicrobials. These aspects will be discussed in this article, together with other important considerations linked to the epidemiology, aetiology and symptoms of TD.
A recognised working definition of the syndrome of TD2 is accepted as: three to four unformed stools in 24 hours and at least one of the following (enteric) symptoms:
Some of the enteric symptoms, such as cramps, abdominal pain and urgency, will occur quite frequently. Vomiting and blood in the stools occurs in less than 10 per cent and fever in up to 30 per cent of cases.
Typically, TD is considered an acute problem and diarrhoea lasting longer than 14 days might be classified as a chronic or persistent diarrhoea, considered by some as a separate entity.3 However, there is some overlap in this classification in that organisms such as Giardia are listed as potential causes of TD; symptoms of infection with this organism can persist for many weeks or months if untreated.
There is also some difficulty in classifying the relative severity of a bout of TD. The following system has been proposed:1
There is a fine line between what symptoms an individual would consider to be tolerable or distressing. For instance, under which category might a person suffering just one or two massive bouts of diarrhoea which they find particularly distressing be placed? The definition of severe diarrhoea is perhaps more helpful, implying a dysentery which would need further investigation with a view to specific antimicrobial therapy.
TD tends to occur towards the end of the first week of travel and over 90 per cent of cases occur within the first two weeks.4
Around 30 per cent of patients may be bed ridden and 40 per cent forced to change their itinerary. Fewer than 1 per cent will require hospitalisation. Only 3 per cent are reported to develop a persistent diarrhoea lasting longer than two weeks and 1 or 2 per cent to have diarrhoea lasting longer than a month. The severity of symptoms does vary to some extent with the pathogen involved and there is a weak association between severity and the likelihood of identifying a responsible pathogen.
The risk of contracting TD has been linked to a number of factors.
Destination The relative risk of TD for various destinations is summarised in Table 1. Under-reporting tends to occur in many of the studies which attempt to assess the scale of the problem and the figures in the higher range are probably more representative. Generally, TD is more likely if visiting countries in the summer months, perhaps reflecting an increase in the local fly population. |
|
|
Length of stay and prior travel There is a relationship between length of stay and a tendency to develop immunity to subsequent bouts of TD. This is supported by the observation that those travelling from one developing nation to another are at less risk than those travelling from industrialised countries.4 The risk to expatriates does fall over time but there is still a substantial occurrence of diarrhoeal illness, as was evident from a study conducted in Nepal.5 Furthermore, the expatriates in this study showed a high level of pathogens present in normal stool samples. It is likely that tolerance can develop to enterotoxigenic E coli (ETEC), but individuals remain susceptible to the other organisms responsible for TD. The important message is that longer term travellers should certainly not treat mild to moderate TD with antibiotics because some immunity should be allowed to develop. The immunity will be lost on returning home and frequent travellers from industrialised countries show the same incidence of TD as infrequent travellers.
It is also likely that inexperienced travellers are at a greater risk of TD (possibly due to inadequate food and water hygeine measures), as are those travelling independently.6
Host factors Age appears to be a risk factor,2 with young adults (20-30 years) being at greater risk than older people. Possible explanations for this age difference might be more adventurous eating habits and less previous immunological exposure to certain pathogens. Children under three years old seem to be at the highest risk. Surprisingly, children of three to six years may have the lowest incidence of all.
Dietary habits This will be dealt with in the next article, but one of the most important risk factors appears to be associated with eating out in restaurants.
It seems to make little difference if staying and eating in a five star hotel or budget accommodation.
Other illness and medication It has recently been found that those with reduced stomach acid are much more prone to TD.7 This is because many pathogens are removed by stomach acid to levels unlikely to cause TD. Therefore, travellers taking proton pump inhibitors (PPIs) and, to a lesser extent, longer acting H2 antagonists, may be at risk of TD.
In patients in whom acid suppression is essential, an H2 antagonist should be given in preference to a PPI and they should be warned about the risks. Possible consideration could be given to antimicrobial prophylaxis if visiting very high risk areas.
The effect of TD on drug absorption has not been widely studied, but a decrease in gastrointestinal tract transit time is theoretically possible. Many travellers to the tropics will be taking malaria prophylaxis and one study has shown that blood levels of proguanil (but not chloroquine) are reduced by TD.8 Travellers should therefore be aware of paying particular attention to precautions against biting insects if this is likely to be a problem. They should not take extra medication except on medical advice.
People who are immunocompromised, eg, those receiving chemotherapy or patients with AIDS who have a low CD4 count, would be at an increased risk of TD. In the young and elderly there may be a greater potential for dehydration as a result of TD. Patients with inflammatory bowel disease (IBD) may experience a worsening of the condition following TD.
A number of non-infectious causes of TD have been proposed. The most important might include:2
These non-infectious causes appear to be supported by the observation that over 50 per cent of stool samples from TD patients prove negative for a pathological organism. However, in many studies, a response rate of over 95 per cent is observed with antimicrobial treatment. Therefore the current view is that the majority of cases of TD are infective in origin, even though a pathogen may fail to be detected by stool culture.
The most common and widely quoted causative agent is enterotoxigenic E Coli(ETEC).9 This bacteria produces a toxin similar to that of Vibrio cholerae, which disrupts sodium pump function in the bowel, resulting in a watery diarrhoea. The incidence of ETEC as the causative agent of TD varies in different parts of the world. It is highest in Latin America with a mean isolation rate of around 40 per cent, in comparison with 30 per cent in parts of Africa and just 16 per cent in Asia.10 However, those figures are mean values and there are large variations: for example, in Latin America studies show results of between 17 and 70 per cent.
The causative agent may also be influenced by the season. For instance, in Mexico, ETEC is more commonly implicated in the summer and rainy season but Campylobacter is more common in the winter.11,12
|
A large range of organisms other than ETEC are known to be responsible for TD. Table 2 gives a crude comparison of the risk of acquiring pathogens in different regions. Unfortunately, it is not always possible to ascertain the likely causative agents from clinical symptoms alone. For instance, although Shigella is more commonly associated with fever and blood in the stools, such symptoms can occasionally also be observed for ETEC. However, in general, ETEC is associated with a milder disease. Some of the important strains of organisms listed in Table 2 are described below. |
|
||
Bacteria Campylobacter has been implicated as a relatively common cause of TD in some areas of the world, in particular Thailand.13 It has been observed to be responsible for a higher proportion of cases of TD than ETEC in the winter months in both Mexico and Morocco.11
Campylobacter tends to cause a longer lasting disease than ETEC and may be preceded by fever. Blood and mucus may be present in the stools, and symptoms of malaise and colic continue after the diarrhoea has resolved.
Aeromonas spp is a potential cause of TD, particularly in Asia. It has not been widely studied but can be associated with a persistent diarrhoea.
Food poisoning by Salmonella spp is a possibility in any situation where hygiene is poor. It is therefore not surprising that this is a regular cause of TD, often associated with reported outbreaks in hotels. The symptoms can vary greatly in severity and duration, lasting from just one or two days to up to three weeks. Septicaemia and systemic invasion are potential complications.
Shigella is responsible for the condition often described as bacillary dysentery. The diarrhoea is usually of abrupt onset, accompanied by fever and vomiting. Mucus and blood may be observed in the stools and other enteric symptoms can be present. Symptoms may persist for two or three weeks.
Parasites These organisms may be more of a concern to longer term travellers. In total, around 5 per cent of cases of TD are caused by parasites.2
Entamoeba histolytica is an unlikely cause of TD, resulting in amoebic dysentery. It has a somewhat slower onset than bacillary dysentery and there is a more formed stool, which has an offensive smell and contains blood and mucus. Fever will be absent. Although symptoms may resolve after a few weeks, there is danger of relapse and complications such as perforation and haemorrhage of the gastrointestinal tract. In addition, organisms can travel from the gastrointestinal tract, resulting in abscess formation in the lung, liver or brain.
Giardia infection has been found more commonly among travellers to Nepal and some parts of Russia and Eastern Europe. It is a potential risk to trekkers and campers using a natural water supply. Recently, it has been identified as a cause of "Bushwalkers diarrhoea" in Tasmania.14 Infection is usually waterborne and it is believed that wild animals may be an important vector. As the organism can interfere with food absorption, a frothy offensive smelling diarrhoea may be produced, accompanied by a great deal of flatulence. The problem can persist for many weeks or months.
Cryptosporidium and Cyclospora are not common causes of TD.15 Cyclospora is a reported cause in Nepal16 and Cryptosporidium has caused problems in contamination of water supplies in recent years in the UK. Diarrhoea caused by these organisms can be persistent and quite severe.
Others Viral disease may account for around 10 per cent of all TD, but cholera is extremely rare in travellers. However, news of cholera outbreaks are frequently enough to deter tourists from visiting particular destinations.17 This is largely unfounded as the massive fluid loss and sudden dehydration associated with classic cholera is now rarely seen in healthy individuals. It is a far more serious problem in a malnourished population, where it is more likely to claim the lives of the young or elderly. In the healthy traveller, cholera can have quite a mild course, with some sufferers perhaps remaining undiagnosed in the belief that they have had no more than a bout of TD.
As the majority of cases of TD respond to an antimicrobial, it might seem reasonable to use such agents prophylactically. The use of Streptotriad by the UK team during the 1960 Olympics in Rome won general admiration for the achievement of fewest cases of diarrhoea.
Agents that can be used for prophylaxis Antimicrobials have been employed in the prophylaxis of TD for many years. Until the 1980s, sulphonamides were generally used. Owing to the development of world wide resistance to these agents, co-trimoxazole can only offer 60 to 70 per cent protection. In addition, the adverse drug reactions of the sulphonamides would make them largely redundant for this indication.
The quinolones are now considered the first choice, providing over 90 per cent protection.3 The recommended dose for ciprofloxacin is 500mg once a day. It must be emphasised that this is a non-licensed indication and physicians should be aware of this fact before prescribing. As will be discussed later, the regimens described for the self treatment of TD using ciprofloxacin are also not covered by the product licence.
The only other products marketed in the UK which have the potential for the prevention of TD are the lactobacillus preparations. Some trials have shown lactobacillus acidophilus to be ineffective in the prevention of TD.18 One preparation containing lactobacillus casei GG has been examined in a few small scale trials and appears to provide a maximum 40 per cent protection.19 At this low level of protection it is important to address the potential for a false sense of security leading to complacency to dietary advice, which would still need to be followed. The good side effect profile of lactobacillus may be an attraction to some travellers who are willing to pay for a product which may only provide partial protection. For the future, genetically modified lactobacillus may hold a potential for use as probiotics in the prevention of TD.
In the US, bismuth salicylate (Pepto Bismol) has been recommended for the prophylaxis of TD.3 It must be taken four times a day to provide around 60 per cent protection. However, it would not be practical to carry sufficient liquid to cover a two week trip and tablets are not available in the UK. In any case, in the UK, TD is not a licensed indication for Pepto Bismol.
In the near future, a vaccine against ETEC should be available, to offer at least partial protection against TD. Similarly, a new oral cholera vaccine seems to offer some cross protection against ETEC.
Indications Perhaps the strongest argument against chemoprophylaxis is that TD is invariably a self limiting condition, which would hardly warrant the continuous use of expensive antimicrobial agents. A consensus development conference in the US ruled that prophylaxis against TD is not warranted.20 Generally, the arguments against such use are:
There may be a few indications for prophylaxis in high risk individuals, eg, those who are immunosuppressed, achlorhydric (as a result of taking PPIs) or who have IBD. The importance of a trip could be a consideration, although, as discussed below, if antimicrobials are to be used at all, self treatment with short courses is the preferred option.
There are three approaches to the management of TD - antimotility agents, oral rehydration and antimicrobial therapy.21
Antimotility agents The most useful agent in this class is loperamide, because of its specific effects on the gastro intestinal tract. Others, such as codeine and diphenoxylate/atropine, are no more effective than loperamide and carry a far higher risk of systemic side effects. Loperamide decreases large bowel motility and therefore, to some extent, promotes an increased reabsorption of fluid.22 However, it is always prudent to maintain fluid intake when using loperamide.
For mild to moderate TD, loperamide will improve symptoms such as faecal frequency and cramping,23 allowing the traveller some freedom to carry on with the planned agenda. It should not be used in children.
There are a few perceived drawbacks to using loperamide, which need to be addressed. Taking it at the maximum dosage for more than a day or so could well lead to a bout of constipation as the TD resolves. Indeed, because of changes in diet and inadequate fluid intake, constipation can be as much a problem for travellers as TD. Another theoretical drawback is that antimotility agents have been shown to prolong infection caused by Shigella,24 presumably because of retention of the organism. Recently manufacturers of loperamide25 have claimed that the product is perhaps under-utilised, with an overemphasis being placed on rehydration alone.
In the case of TD, where the inconvenience of bouts of diarrhoea are an important consideration, loperamide does have a useful role.
An approach to using loperamide in TD might be to use it for mild to moderate TD where there is no fever or blood in the stools It should preferably be reserved for use in situations where TD may affect travel plans and for not longer than 24 hours. It should be used in addition to maintaining good hydration.
Oral rehydration The use of oral rehydration solutions in the management of diarrhoeal illness has saved millions of lives in developing countries. The balance of salt and glucose (or other carbohydrate) allows the most efficient absorption of fluid. The addition of potassium and bicarbonate also helps to correct electrolyte imbalance. The use of oral rehydration solutions in diarrhoeal illness in the very young and elderly is well established. However, in otherwise healthy adults it has been suggested that they are unnecessary when managing TD, which is not usually a dehydrating disease in this age group. Simply maintaining fluid intake using sugary drinks and eating, for instance, salt crackers, should suffice in healthy adults.
A case may still be made for some travellers to carry electrolyte sachets for emergency use as the more intrepid traveller may not have suitable soft drinks or foods readily to hand. It may also be necessary for such travellers to make up their own solution using salt and sugar; a suitable formula is half a teaspoon of salt and eight level teaspoons of sugar in one litre of clean water. Honey could be substituted if sugar is not available.
Children and the elderly should use commercial rehydration sachets (eg, Dioralyte, Rehidrat). Although these are readily available overseas, they usually contain the higher sodium content World Health Organisation (WHO) formulation, which can be less palatable.
Maintaining fluid intake can also help to improve general symptoms and well-being, although faecal fluid output can actually increase with aggressive rehydration therapy.4 Whether or not electrolyte solutions offer any benefit to adults over simply increasing fluid intake has not been studied.
More recently, a starch based product (Dioralyte Relief) has been marketed and claimed to be more efficient than glucose formulations. An additional advantage is that the starch based product would form a more solid stool. Whether this product offers any specific advantages to sufferers of TD needs further study.
Antimicrobial therapy Self treatment of TD with antimicrobials can be very successful. Whether or not travellers should be supplied with such agents is a contentious issue.
At one time, co-trimoxazole was considered the antimicrobial of choice for the empirical treatment of TD. This has now been replaced by the quinolones which have been shown in a number of trials to be highly effective.1 When a quinolone is supplied to travellers for self treatment at the first sign of diarrhoea, both severity and duration of the illness are reduced.13,26 The regimens employed vary. It has been demonstrated that a single 500mg dose of ciprofloxacin will reduce the mean duration of TD to under 24 hours.27 If symptoms should persist on the second day, after single dose therapy, a three to five day course (500mg twice a day) might be advisable.
There are some important considerations when supplying such therapy to travellers. As has been mentioned, TD is not a licensed indication for ciprofloxacin. Also, the regimens usually employed are not those covered by the product licence for infective diarrhoea, the usual length of therapy being five to seven days.
As shown in Table 3, ciprofloxacin is effective against many, but not all, of the responsible pathogens. Campylobacter may respond to a quinolone,28 but treatment failures and reccurrence have been reported13 and erythromicin is the usual drug of choice. Cyclospora is only sensitive to co-trimoxazole and Cryptosporidium responds to no available agents. For Giardia or amoebic dysentery, metronidazole or tinidazole is required.
|
There is no internationally accepted consensus on the place of antimicrobials in treating TD. If an antimicrobial is to be used, then travellers may be supplied with a course of ciprofloxacin and instructed to use them as described in the bottom half of Table 4.1 In the US, bismuth salicylate would also be considered as an option for mild TD, as around 60 per cent of cases may improve with such treatment. This approach is generally not followed in the UK, where the regimen described in the top half of Table 4 would be considered more appropriate for most travellers. The instructions given are therefore to seek medical attention if there is blood in the stools, fever is present and/or the diarrhoea persists for more than five days. This assumes that such help is available and that the appropriate antimicrobials can be easily obtained. For the minority of travellers on longer trips to developing countries, this may not be the case and, in my opinion, antimicrobials should be carried; both ciprofloxacin and metronidazole may be needed. The advice should always be to use such medication under medical supervision. In comparatively rare circumstances, ie, when travelling to very remote regions, individuals might need to be instructed on self medication, particularly if a more severe or persistent diarrhoea develops.
Table 4: Management of travellers' diarrhoea |
|||
| Group | Severity of diarrhoea | ||
| Mild | Moderate | Severe | |
| Travellers not carrying antimicrobials | Fluid replacement (loperamide if required) | Fluid replacement and a short course of loperamide | Seek medical help |
| Travellers carrying an antibiotic | Fluid replacement (loperamide if required) | Loperamide and quinolone (single dose/short course) | Quinolone 3-5 days and metronidazole if longer than 14 days |
For young children, the recommended approach to treating acute diarrhoea of any cause should be followed, with an emphasis on oral rehydration.
Dietary restriction is not necessary in adults or children, but given a tendency for certain foods to increase gastrointestinal motility, eating more bland foods (eg, bread, potatoes, bananas) may help with symptoms.
A more difficult question relates to the demands of a businessman or politician on an important trip, where time is critical. There is evidence that combining a single 500mg dose of ciprofloxacin with loperamide after the first loose stool will resolve TD more quickly, particularly if caused by ETEC.13,26 Although ciprofloxacin is not licensed for this regimen, there may occasionally be circumstances when it is prescribed. The argument for antimicrobial treatment can be justified on pharmacoeconomic terms, where cost of therapy would be less than the cost of the time lost on the trip.29 It is also of interest to note that it may well be the treatment of choice for those in the medical profession; 25 per cent of microbiologists attending a conference overseas were found to be carrying antimicrobials for TD.30
In about 3 per cent of cases, symptoms persist for longer than 14 days and inevitably the returning traveller will seek medical help.31 Such cases should of course always be referred when presented at a pharmacy.
There are a number of reasons for persistent diarrhoea; giardiasis is one of the most important, although the other parasites listed in Table 2 may also be responsible. Bacterial infections can also cause a persistent diarrhoea, especially Shigella and Aeromonas spp. Occasionally, E coli, particularly the enteropathogenic forms, can cause a longer lasting diarrhoea.
The aetiology is somewhat complicated by non-infectious causes of persistent diarrhoea. Repeated GIT infection can lead to disruption of gut function, contributing to malabsorption syndromes such as tropical sprue (a severe malabsorption syndrome accompanied by diarrhoea). Another potential scenario is a bout of diarrhoea causing disruption of gut flora which then takes some time to resolve. It is possible that this sort of post-diarrhoeal syndrome is actually made worse by repeated courses of antibiotics. There have also been cases where TD has unmasked a latent IBD.
On presentation of the patient to a GP, a stool sample would usually be taken. The presence of an organism in the stool does not necessarily mean that it is the responsible organism, eg, Entamoeba cysts may be present even in the absence of clinical dysentery. Likewise, despite a negative stool sample, an infective organism may still be responsible.
Empirical treatment may therefore be indicated if negative results are obtained and, in some circumstances, the physician will wish to commence such treatment while awaiting results. Suitable empirical treatment would begin with a full five day course of ciprofloxacin. If this should fail, then metronidazole or tinidazole could be used to deal with Giardia. Further investigations should be carried out for other causes of persistent diarrhoea; in particular Entamoeba infection should be excluded.
If a positive culture is obtained then the identified organism should guide therapy as indicated in Table 3.
Entamoeba infection can be hard to eradicate, resulting in reccurrence of symptoms, so a course of the amoebicide diloxanide furoate should be given, following treatment with metronidazole.
Dr Goodyer is director of pharmacy practice research at King's College London, and superintendent of Nomad Travel Pharmacy
| 1. Caeiro J, DuPont HL. Management of travellers' diarrhoea. Drugs 1998;56:73-81.[Medline reference] |
| 2. Peltola H, Gorbac SL. Travellers' diarrhoea: epidemiology and clinical aspects. In: DuPont HL, Steffen R, editors. Textbook of travel medicine and health. Hamilton, Canada: BC Decker, 1997:78-86. |
| 3. Ericsson CD, Rey M. Prevention of travellers' diarrhoea: risk avoidance and chemoprophylaxis. In: DuPont HL, Steffen R, editors. Textbook of travel medicine and health. Hamilton, Canada: BC Decker, 1997:86-91. |
| 4. Ericsson CD. Travellers' diarrhoea: epidemiology, prevention and self treatment. Infect Dis Clin North Am 1998;12:285-303. [Medline reference] |
| 5. Hoge CW, Shlim DR, Echeverria P, Rajah R, Herrmann JE, Cross JH. Epidemiology of diarrhoea among expatriate residents living in a highly endemic environment. JAMA 1996;27:533-8.[Medline reference] |
| 6. Cobelens FG, Leentvaar-Kuijpers A, Kleijnen J, Coutinho RA. Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice. Trop Med Int Health. 1998;3:896-903.[Medline reference] |
| 7. Stop PPI before travel, expert advises. Pharm J 1998;261:695. |
| 8. Behrens RH, Taylor RB, Low AS, Warburton B, Pryce D. Travellers' diarrhoea; a controlled study of its effects on chloroquine and proguanil absorption. Trans R Soc Trop Med Hyg 1994;88(1):86-8.[Medline reference] |
| 9. Levine MM. Escherichia coli that cause diarrhoea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic and enteroadherent. J Infect Dis 1987;155:377-89.[Medline reference] |
| 10. Black RE. Epidemiology of travellers' diarrhoea and relative importance of various pathogens. Rev Infect Dis 1990;12(Suppl 1):S73-9. |
| 11. Mattila L, Siitonen A, Kyronseppa H, Simula J, Oksanen P, Stenuik M et al. Seasonal variation in aetiology of travellers' diarrhoea. J Infect Dis 1992;165:385-8.[Medline reference] |
| 12. Mattila L. Clinical features and duration of travellers' diarrhoea in relation to its aetiology. Clin Infect Dis 1994;19:728-34. [Medline references] |
| 13. Petruccelli BP, Murphy GS, Canchez JL, Walz S, DeFraites R, Gelnett J, et al. Treatment of travellers' diarrhoea with ciprofloxacin and loperamide. J Infect Dis 1992;165:557-60. [Medline reference] |
| 14. Kettlewell JS, Bettiol SS, Davies N, Milstein T, Goldsmith JM. Epidemiology of giardiasis in Tasmania: A potential risk to residents and visitors. J Travel Med 1998:5:127-31. [Medline reference] |
| 15. Jelinek T, Lotze M, Eichenlaub S, Loscher T, Nothdurft HD. Prevalence of infection with cryptosporidium parvum and cyclospora cayetansis among international travellers. Gut 1997;41:801-4. [Medline reference] |
| 16. Crowley B, Path C, Moloney C, Keane CT. Cyclospora species: A cause of diarrhoea among Irish travellers to Asia. Irish Med J 1996;89:110-2. [Medline reference] |
| 17. Behrens R. Cholera. In: Dawood R, editor. Travellers' health. Oxford: Oxford University Press, 1992. |
| 18. Katelaris P, Salam I, Farthing MJG. Lactobacilli to prevent travellers' diarrhoea. New Eng J Med 1995;333:1360-1. [Medline reference] |
| 19. Dupont HL. Lactobacillus GG in prevention of travellers' diarrhoea: An encouraging first step. J Travel Med 1997;4:1-2. [Medline reference] |
| 20. Gorbach SL, Edelman R, editors. Travellers' diarrhoea: National Institutes of Health Consensus Development Conference. Rev infect dis 1986;8(Suppl 2):S1285-9. |
| 21. Petrucceli BP, Kollaritsch H, Taylor DN. Treatment of travellers' diarrhoea. In: Dawood R, editor. Travellers' health. Oxford: Oxford University Press, 1992. |
| 22. Guabdalini S, Fasano A, Rao MC et al. Effects of loperamide on intestinal ion transport. J Paediatr Gastroetnerol Nutr 1984;3:593-601. [Medline reference] |
| 23. Johnson PC, Dupont Herbert L, Morgan, Bitsura, Wood LV. Comparison of loperamide with bismuth salicylate for the treatment of acute travellers' diarrhoea. JAMA 1988;255:757-60. [Medline reference] |
| 24. DuPont HL, Hornick RB. Adverse effects of Lomotil therapy in shigellosis. Ibid 1973;226:1525-8. [Medline reference] |
| 25. Review guidelines for diarrhoea treatment, says pharmaceutical company. Pharm J 1999;263:9. |
| 26. Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travellers' diarrhoea: ciprofloxacin plus loperamide compared to ciprofloxacin alone. Ann Intern Med 1991;114 :731-4. [Medline reference] |
| 27. Sama I, Kateelaris P, Leigh-Smith S, Farthing MJG. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994;344:1537-9. [Medline reference] |
| 28. Gallardo F, Gascon, Ruiz J, Corachan M, Jimenez de Anta M, Vila J. Campylobacter jejuni as a cause of travellers' diarrhoea: clinical feature and antimicrobial susceptibility. JTravel Med 1998;5:23-6. [Medline reference] |
| 29. Thompson MA, Booth IW. Treatment of travellers' diarrhoea: economic aspects. Pharmacoeconomics 1996;9(5): 82-91. |
| 30. Ala'Aldeen-DA. A microbiologist's guide to travellers abroad: do as I say not as I do. J Hosp Infect 1997; 5:255-7. [Medline reference] |
| 31. Dupont HL, Capsuto EG. Persistent diarrhoea in travellers. Clin Infect Dis 1996;22:124-8. |